Tinengotinib clinical trials
Also written TT-00420.
How each study uses tinengotinib is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the tinengotinib studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your alerts, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your alerts. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
12 studies that test it; most in 2026 (3)
| Year | Studies |
|---|---|
| 2019 | 1 |
| 2020 | 1 |
| 2021 | 2 |
| 2022 | 1 |
| 2023 | 2 |
| 2024 | 1 |
| 2025 | 1 |
| 2026 | 3 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 11 · Other 1
TransThera Sciences (Nanjing), Inc. (10) · The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School (1) · Akeso (1)
Related medicines
As reviewed, each with the page that says it.
Coming up
From the study records. Dates are the sponsors’ own estimates and often move.
Reaching primary completion within a year · 3, 1 in phase 3
Studies that test tinengotinib, phase 3 first.
- Dec 2026Study of Tinengotinib VS. Physician's Choice a Treatment of Subjects With FGFR-altered in CholangiocarcinomaPhase 3 · TransThera Sciences (Nanjing), Inc.
- May 2027A Phase II Clinical Study of AK104/AK112 in Combination With TT-00420 Tablet for Advanced HCC.Phase 2 · Akeso
- Jun 2027Efficacy and Safety of Tinengotinib Tablets Combined With Fulvestrant Injection in Patients With HR Positive and HER-2 Negative Recurrent or Metastatic Breast Cancer Who Have Failed Prior TreatmentPhase 2 · TransThera Sciences (Nanjing), Inc.
Studies
Open first, then newest update. How each study uses tinengotinib is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 12
- Safety, Efficacy and Pharmacokinetics of TT00420 Tablets Combined With Novel Endocrine Therapy in Patients With Metastatic Castration-resistant Prostate Cancer (mCRPC)RecruitingPhase 2TransThera Sciences (Nanjing), Inc.NCT07871110Written as tinengotinib 10 mg QD plus darolutamide
- Efficacy and Safety of Tinengotinib Tablets Combined With Fulvestrant Injection in Patients With HR Positive and HER-2 Negative Recurrent or Metastatic Breast Cancer Who Have Failed Prior TreatmentRecruitingPhase 2TransThera Sciences (Nanjing), Inc.NCT07498478Written as Tinengotinib
- A Phase II Clinical Study of AK104/AK112 in Combination With TT-00420 Tablet for Advanced HCC.RecruitingPhase 2AkesoNCT07052253Written as TT-00420 (tinengotinib)
- Efficacy and Safety of TT-00420 (Tinengotinib) Tablets Versus Chemotherapy in Patients With Advanced Intrahepatic Cholangiocarcinoma Harboring FGFR2 Fusions/Rearrangements or MutationsNot yet recruitingPhase 3TransThera Sciences (Nanjing), Inc.NCT07328919Written as TT-00420 (tinengotinib)
- Safety and Efficacy of TT-00420 Tablets Combined With Toripalimab Injection in Advanced Urological TumorsNot yet recruitingPhase 1/2The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical SchoolNCT06221774Written as TT-00420 + Toripalimab
- Study of Tinengotinib VS. Physician's Choice a Treatment of Subjects With FGFR-altered in CholangiocarcinomaActive, not recruitingPhase 3TransThera Sciences (Nanjing), Inc.NCT05948475Written as Tinengotinib 8 mg
- Study of TT-00420 (Tinengotinib) in Subjects With Cholangiocarcinoma Who Failed or Relapsed to Chemotherapy and FGFR InhibitorActive, not recruitingPhase 2TransThera Sciences (Nanjing), Inc.NCT06057571Written as TT-00420 (tinengotinib)
- Safety of TT-00420 (Tinengotinib) Monotherapy in Patients With Advanced Solid Tumors and Triple Negative Breast CancerCompletedPhase 1TransThera Sciences (Nanjing), Inc.NCT03654547Written as TT-00420
- To Evaluate Efficacy and Safety of TT-00420 (Tinengotinib) as Monotherapy and Combination Therapy in Patients With Advanced Solid TumorsCompletedPhase 1/2TransThera Sciences (Nanjing), Inc.NCT05253053Written as TT-00420
- Study to Evaluate the Efficacy and Safety of TT-00420 (Tinengotinib) in CholangiocarcinomaCompletedPhase 2TransThera Sciences (Nanjing), Inc.NCT04919642Written as TT-00420
- Study of TT-00420 (Tinengotinib) Tablet as Monotherapy and Combination Therapy in Patients With Advanced Solid TumorsCompletedPhase 1/2TransThera Sciences (Nanjing), Inc.NCT04742959Written as TT-00420
- Relative Bioavailability Study and Food Effect Study of TT-00420 (Tinengotinib) Capsule and Tablet Formulations in Healthy VolunteersCompletedPhase 1TransThera Sciences (Nanjing), Inc.NCT04705922Written as TT-00420 Capsule
Given beside what is tested · 1 — tinengotinib is usual care or a partner of the new treatment
Codes
What other systems call tinengotinib · ClinicalTrials.gg INT018403
- UNII (FDA) WZ9TJ0L9Y8TINENGOTINIBOne source FDA
- NCI Thesaurus C162532TinengotinibOne source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| UNII (FDA) | WZ9TJ0L9Y8 | TINENGOTINIB | One source FDA |
| NCI Thesaurus | C162532 | Tinengotinib | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.